glp-1 news today october 20 2025 Impact: How GLP-1s Are Changing the Diabetes Treatment Paradigm ISPOR 2025: Exploring reasons for

After treatment, hASC did not exhibit a significant change in metabolic activity as measured by MTT assay

A new Cleveland Clinic analysis of nearly 8,000 patients suggests that discontinuing semaglutide and tirzepatide, on average, does not lead to significant weight regain in clinical practice, as many patients later restart the original medication or try an alternative obesity treatment

Monday Poster Session Category: Small Intestine P4045 - Comparative Risk of Small Intestinal Bacterial Overgrowth (SIBO) Among Patients Using GLP-1 Receptor Agonists: A Real-World Analysis Using TriNetX Monday, October 27, 2025 10:30 AM - 4:00 PM PDT Location: Exhibit Hall Has Audio Presenting Author(s) Lina AlQirem, MD 1 , Suria Devarapalli, DO 1 , Adalberto Guzman, MD 2 , Murad Qirem, MD 3 , Meer A

4.7 Combined use of SGLT2i and GLP-1 RAs Several studies have explored the combination of GLP-1 RAs and SGLT-2 inhibitors in patients with T2DM